middle.news
Immutep’s IMP761 Shows Promising Immunosuppressive Effects in Phase I Trial
8:34am on Monday 22nd of December, 2025 AEDT
•
Healthcare
Read Story
Immutep’s IMP761 Shows Promising Immunosuppressive Effects in Phase I Trial
8:34am on Monday 22nd of December, 2025 AEDT
Key Points
Phase I trial completed 2.5 and 7 mg/kg dosing levels with positive safety data
IMP761 showed dose-dependent immunosuppressive effects on T cell activity
No serious treatment-related adverse events reported, only mild reactions
Trial to continue with updates anticipated in first half of 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE